D.A. Gros

DRUG DEVELOPMENT - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer David-Alexandre C. Gros, MD, explains how researchers are targeting strategies in immunosuppression that can help donated kidneys remain healthy and viable for much longer post-transplant, thus allevi...

Thank you Drug Development & Delivery for inviting me to provide an overview of
advances in #ELDN’s research targeting the CD40L pathway to help prevent rejection in organ and islet transplantation:

drug-dev.com/drug-develop...

Two Type 1 diabetes patients are potentially the 1st human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy (tegoprubart by Eledon Pharmacuticals) in clinical trial run by U Chicago Medicine Transplant Institute goodmorningamerica.com/wellness/story

Switching off autoimmunity Discovered 30 years ago, CD40L antagonists are proving to be powerful autoimmune drugs

In this new perspective in Science, my role model and favorite immunologist Randy Noelle discusses the development of CD40L antagonists to treat autoimmunity:

www.science.org/doi/10.1126/...

New anti-CD40L
'AT-1501, as a monotherapy & in conjunction with other immunosuppressive agents to prevent graft rejection in NHPs. Encouragingly, AT-1501 promoted survival and function of islet and kidney allografts in cynomolgus & rhesus macaques, respectively, without evidence of thromboembolism.'